Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?

Over the past few decades, the widespread availability of improved sequencing techniques has contributed immensely to our understanding of the cancer genome and therefore also to our knowledge of clinically actionable mutations in brain tumors. The discovery of a variety of genetic driver mutations in these tumors has enabled us to integrate these findings into the diagnostic process and to implement targeted treatment strategies in affected patients by directing them to appropriate clinical trials. Here we summarize recently discovered driver mutations in low-grade gliomas, glioblastomas (GBMs), craniopharyngiomas, and meningiomas and discuss the diagnostic and therapeutic implications of these findings. TARGETED TREATMENT OF LOW-GRADE GLIOMA Section: ChooseTop of pageAbstractTARGETED TREATMENT OF LOW... <